GlassScriptPhysician profile
Michele Maholtz
NPI 1205807161
$4,443.44
in general payments reported to CMS, 2019-2025
30 companies · $115 in 2025
The $115 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,612 · 2020: $1,373 · 2021: $16.47 · 2022: $24.11 · 2023: $279 · 2024: $23.54 · 2025: $115.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $401 · Education: $16.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $401.19 |
| Education | $16.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $543.67 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $540.54 | 2019-2020 | |
| Mylan Specialty L.P. | $494.27 | 2019-2020 | |
| Abbvie INC. | $404.86 | 2023-2025 | |
| Glaxosmithkline, LLC. | $390.38 | 2019-2020 | |
| Grifols USA, LLC | $259.00 | 2019-2020 | |
| Genentech USA, INC. | $206.18 | 2019 | |
| Genzyme Corporation | $184.13 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $153.93 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $142.30 | 2019 | |
| Harmony Biosciences LLC | $134.67 | 2020 | |
| Shire North American Group INC | $118.42 | 2019 | |
| Boston Scientific Corporation | $101.04 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $98.32 | 2019-2020 | |
| Advanced Respiratory, INC | $93.99 | 2019-2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $83.93 | 2019-2020 | |
| Medline Industries LP | $82.66 | 2019 | |
| Insmed, INC. | $64.63 | 2019-2020 | |
| Pfizer INC. | $53.13 | 2019-2020 | |
| Allergan, INC. | $40.58 | 2021-2022 | |
| Circassia INC. | $37.51 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $37.46 | 2020 | |
| Csl Behring | $33.64 | 2019 | |
| Philips North America LLC | $33.58 | 2020 | |
| Arbor Pharmaceuticals, INC. | $30.88 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $26.47 | 2019 | |
| Nabriva Therapeutics, Plc | $24.51 | 2020 | |
| Electromed, INC. | $15.53 | 2019 | |
| Next Science LLC | $13.23 | 2023 | Xperience, Blastx, Surgx |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$0.05 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michele Maholtz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.